TD Cowen analyst Ritu Baral raised the firm’s price target on Praxis Precision (PRAX) to $353 from $251 and keeps a Buy rating on the shares. The firm noted they presented updated Ph2 RADIANT and key interim EMBOLD data. In FOS, vormatrigine led to a roughly 100% median seizure reduction by wee 8, with seizure frequency declining over time. Also, a roughly 80% median seizure reduction was seen in generalized epilepsy.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision provides clinical updates at AES annual meeting
- Praxis Precision price target raised to $315 from $304 at Needham
- Praxis Precision price target raised to $507 from $499 at BTIG
- Promising Clinical Data and Strategic Developments Drive Buy Rating for Praxis Precision Medicines
- Midday Fly By: Netflix to buy Warner Bros., HP Enterprise posts mixed Q4